RxDoctor Payments Data

Alanna Coolong, MD

Interventional Cardiology · Hyannis, MANPI 1972604254

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Medtronic at 42.7% of the total. Reporting peaked in 2023 at $282 and has fallen 85.1% since, to $42 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MA, where the typical reported total is $3,030.

$993in general payments, 2019–2025

Across 24 payments — averaging $41.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$424
  • Edwards Lifesciences$363
  • Abbott$62
  • Lexicon Pharmaceuticals, Inc.$59
  • Boston Scientific$26
  • E.r. Squibb & Sons, L.L.C.$23
  • plus $37 from 2 others
$28,407in research payments, 2019–2025

Across 11 payments — averaging $2582.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$28K

What the payments were for

  • Food & beverage$993100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$993 in reported general payments places this provider in the 25th percentile of 128 interventional cardiology providers in Massachusetts.

See all interventional cardiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$161,652
Medicare patients
328
Services billed
853

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$6,960
ClopidogrelClopidogrel Bisulfate20$241
Atorvastatin Calcium22$221
Metoprolol Succinate17$193
Pantoprazole Sodium30$164

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →